Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hansoh Enters $170 Million Agreement for Endometriosis/Uterine Fibroid Therapy

publication date: Aug 9, 2022

Shanghai Hansoh Pharma acquired Greater China rights to a therapy for endometriosis, uterine fibroids and other indications from Korea’s TiumBio in deal worth up to $170 million. TU2670, an oral active non-peptide GnRH antagonist, has successfully completed two Phase I trials. TiumBio believes the candidate offers causes side effects than the current standard of care. TiumBio is an R&D-focused biopharma that develops innovative small molecule and biologic medicines. Hansoh will pay $6 million in upfront costs and up to $164 million in milestones, plus royalties. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.